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Abstract: 
Background: Adults with human immunodeficiency (HIV) infection commonly 
experience fractures and have a high prevalence of osteoporosis. The reasons for low 
bone mineral density (BMD) in HIV patients are multifactorial and there are now 
guidelines for screening. The aims of this study were to determine the screening 
practices for osteoporosis at this sexual health clinic, the prevalence of osteoporosis 
and to examine the risk factors for bone disease. 
Methods: We performed a retrospective cohort study of all HIV patients attending the 
Sunshine Coast Health Service District Sexual Health Clinic. Via chart review we 
collected the following details: patient demographics, co-morbid conditions, HIV 
status and anti-retroviral therapy, BMD screening, fractures, screening for secondary 
causes of bone disease, and treatment interventions for osteoporosis. 
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Results: 243 patients with HIV attended the sexual health clinic.  Of these, 149 met 
screening criteria for BMD assessment and 93 (61%) of those eligible underwent 
BMD examination. In those who had a BMD performed, 13 (19%) had sustained a 
previous fracture, 28 (30%) had osteoporosis, 42 (45%) had osteopenia. In the 
osteoporosis group, 21 (78%) were treated with vitamin D and calcium, 7 (26%) had a 
change in ART, 19 (68%) were treated with anti-resorptive therapy and 9 received 
testosterone replacement.  
Conclusions: 
In this cohort, there was a high prevalence of low bone mass and BMD screening 
rates of 60%. Our results highlight the importance of this condition and the need to 
improve screening and availability of BMD assessment. 
 
Introduction: 
Adults with human immunodeficiency virus (HIV) infection more commonly 
experience fractures and are found to have osteoporosis more frequently than adults 
without HIV infection.(1),(2)  In a meta-analysis that examined incident fractures in 
people living with HIV, the pooled estimate incidence rate ratio (IRR) was 1.58 for all 
fractures and 1.35 for fragility fracture.(2) The  prevalence of osteoporosis has also 
been shown to be three times higher among people living with HIV, compared to 
HIV-negative control subjects.(1) A study of over 50000 people living with HIV 
demonstrated a prevalence of osteoporosis of approximately 15%.(3) 
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The reasons for low bone mineral density (BMD) in HIV are multifactorial and are 
thought to be due to the combination of HIV infection, established osteoporosis risk 
factors, high rates of tobacco and alcohol use and anti-retroviral therapy (ART).(4) 
Certain agents, such as the nucleoside reverse transcriptase inhibitor tenofovir 
disoproxil fumarate (TDF), have been more strongly associated with decreases in 
BMD.(5) In the ASSERT study, ART naïve patients were randomized to TDF or 
abacavir/lamivudine with efaverinz and BMD was assessed at 48 weeks. Greater 
decreases in BMD and increases in bone turnover were observed in the TDF group, 
with 13% having >6% loss at the hip and 15% had >6% loss at spine compared to 3% 
and 5% respectively in the abacavir/lamivudine group.(5) Protease inhibitors have 
also been implicated though to a lesser extent.(6) A new formulation of tenofovir, 
tenofovir alafenamide (TAF), has recently become available for use in Australia. TAF 
is a prodrug of tenofovir and is metabolized to tenofovir intracellularly resulting in 
higher intracellular concentrations of the active metabolite, tenofovir-diphosphate, 
and lower plasma levels of tenofovir, compared with TDF. Due to this, a smaller dose 
is required, limiting renal and bone toxicity.(7) A recent systematic review of six 
randomized controlled trials (RCTs) demonstrated that patients in the TAF group had 
significantly less reduction in bone mineral density than those in the TDF group at 48 
weeks.(7) This is in contrast to a subsequent meta-analysis that demonstrated a 
difference in bone and renal adverse effects only when TDF was boosted with 
ritonavir or cobicistat.(8) As a result, in our institution, patients at high risk of 
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developing low bone mass have been switched from TDF to TAF to reduce treatment 
related morbidity associated with TDF. 
 
For people living with HIV, the European AIDS Clinical Society (EACS) guidelines 
recommend screening for osteoporosis in the following situations:(9) 
1. Post-menopausal women 
2. Men 50 years of age or older 
3. History of low impact fracture 
4. High risk for falls 
5. Clinical hypogonadism 
6. Oral glucocorticoid use 
 
The recommendation for screening men 50 years of age or older is supported by other 
guidelines, recommending that the test is repeated in 2-5 years if no treatment is 
indicated.(4) The cost-effectiveness of this approach has not been evaluated.(10) If 
the result indicates osteopenia, the 10-year fracture risk should be evaluated using the 
WHO Fracture Risk Assessment Tool (FRAX).(11) If the 10-year risk of all 
osteoporotic fracture is e  20% or the risk of hip fracture is e  3%, therapy should be 
considered. In 2009, our group published a study of 180 HIV-infected outpatients 
attending a Sexual Health and HIV Clinic in Nambour, Queensland, Australia.(12) 
Results showed that 22 (12%) patients had a history of a fracture, five due to 
osteoporosis, and only three had bone mineral density assessed.  High rates of 
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smoking and alcohol use, known risk factors for low bone density, were found.  
Following this study, a care plan was put in place to improve the detection and 
management of comorbid conditions, including osteoporosis. 
 
This study aims to build on our previous work to determine the current screening 
practices for osteoporosis at this clinic and the prevalence of osteoporosis, osteopenia 
and fractures in this cohort. In addition, this study aims to determine the 
characteristics of patients with osteoporosis. 
 
Methods: 
Study population:  
A retrospective cohort study was conducted of all people living with HIV who were 
attending the Sunshine Coast Health Service District Sexual Health Clinic (Clinic 87). 
Patients who attended the clinic between June 2016 and June 2017 were included. 
Patients who had attended the clinic transiently and had no further follow-up were 
excluded. Patients were de-identified and a single person chart review was conducted 
using a proforma of predetermined variables. Information was collected from patient 
records, the institution pathology, and radiology database.  
 
Definitions: 
Osteoporosis and osteopenia were defined using the European AIDS Society 
guidelines.(9) Osteoporosis was defined as a T-score of -2.5 for men over 50 or post-
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menopausal women or a Z-score <-2.0 for pre-menopausal women or men <50 years 
of age with a fragility fracture. Osteopenia was defined as a T-score between -1.0 and 
-2.5 in post-menopausal women and men 50 years of age or over. Fragility fracture 
was defined as a fracture from a fall from standing height or less.(9) The fracture risk 
assessment tool was used to calculate FRAX scores.(11)  Hypogonadism was defined 
as detection of testosterone level below the normal limit (<9 nmol/L) and confirmed 
by review of an endocrinologist, though we acknowledge that this diagnosis at times 
can be controversial.  
 
Variables and outcomes:  
Data collected included, patient details, details on screening with BMD, presence of 
fractures and FRAX score, screening for secondary characteristics and interventions 
for osteoporosis. Patient details included age (years), sex, smoking, co-morbidities 
e.g. Type 2 Diabetes Mellitus, hepatitis C co-infection, duration HIV infection 
(years), antiretroviral therapy and any prior or current exposure to TDF or Protease 
inhibitors for >one-year, viral load suppression and nadir CD4 count (cells/mm3), 
glucocorticoid use and BMI. Details on screening with BMD included Z and T scores 
and secondary characteristics screened for were vitamin D, testosterone (ng/dL), 
thyroid function, parathyroid hormone, calcium, phosphate and renal function. 
Interventions for osteoporosis included change in anti-retroviral therapy and 
osteoporotic treatment.  
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Outcomes assessed included the proportion of patients attending the clinic eligible for 
osteoporosis screening according to the EACs guidelines and subsequently, the 
proportion screened.7 In addition, in those screened with BMD, we assessed the 
prevalence of osteoporosis, osteopenia and fractures, associated characteristics of 
those with low bone mass (osteoporosis or osteopenia), and treatment interventions 
for osteoporosis.  
 
Statistical analysis: 
Data was collated in a Microsoft excel spreadsheet and analyzed using the statistics 
package, SAS ® software.  Descriptive analysis was performed to describe the 
demographics and comorbidities of the screened cohort (mean and SD for continuous 
variables), as well as rates of screening, prevalence of osteoporosis, osteopenia and 
fractures and treatment interventions.  In those screened, a multi-variate logistic 
regression was conducted to assess for association between various known risk factors 
and osteoporosis as well as a test of proportions. Significance was set at p=<0.05. 
Ethics approval was gained from the Institutional Review Board (HREC) of the Royal 
Brisbane and Women’s hospital in accordance with the National Statement on Ethical 
Conduct in Human Research. 
 
Results: 
Screening: 
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There were 243 people living with HIV identified attending the Sunshine Coast 
Sexual Health Clinic. According to the EACS criteria, 149 (61%) of the total 
population were eligible for screening. Of those, 93 (63%) were screened with bone 
mineral density (BMD). Out of those screened, 42 (45%) had osteopenia and 28 
(30%) had osteoporosis (Figure 1).  Table 1 shows the baseline characteristics for 
those screened. The population was predominantly male with high rates of smoking.  
There was no difference in history of TDF or protease inhibitor exposure between 
those with low bone mass or without but there were increased rates of low BMI and 
fractures (both all fractures and fragility) in the group with low bone mass.  
 
In those with osteoporosis, 75% were treated with vitamin D and calcium and 68% 
were referred to the endocrinology department and commenced on anti-resorptive 
therapy. Half of the cases with osteoporosis were screened for secondary causes 
(TSH, PTH, Vitamin D, Ca2+,PO4
3-, GFR, serum protein electrophoresis, 
testosterone/oestrogen). FRAX score was calculated in only four patients at the clinic. 
Retrospective calculations revealed that two of those with osteopenia met criteria for 
treatment on the basis of their FRAX score.  
 
Antiretroviral exposure: 
A significant proportion of the population had a history of current or past TDF 
exposure and within those with low bone mass, 79% had been exposed to TDF. In the 
group with low bone mass, only 15 (27%) of those previously treated with TDF 
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remained on TDF following diagnosis of low bone mass, which, was statistically 
significant (Table 1); 25 (45%) were transitioned to TAF and 15 were changed to a 
tenofovir-free regimen. There was also significant exposure to protease inhibitors in 
the population. 
 
Risk factors: 
To investigate for risk factors for osteoporosis in this cohort, a multi-variate logistic 
regression was conducted in those who had a DEXA performed to evaluate for 
association between osteoporosis and age, sex, smoking, hypogonadism, current TDF 
exposure and duration of HIV. No statistical significance was found. However, a 
difference in proportions of low bone mass in patients with and without 
hypogonadism was statistically significant, (p = 0.05.)  
 
Discussion: 
In this study, over half (61%) of patients were eligible for screening for osteoporosis 
with BMD and 63% of these patients underwent BMD examination.  Although this 
was a general improvement from earlier years, many were still not screened and 
FRAX score assessment was done infrequently. Half those who had FRAX scores 
calculated should have received treatment based on their score according to current 
recommendations.(11) 
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Possible reasons for this include the price of BMD examination, difficult access and 
lack of clinician and patient awareness of the importance of low bone mass. 
Currently, there is no Medicare rebate for a DEXA scan for people living with HIV 
between the age of 50 and 70 so access is limited by public hospital availability, 
which is quite variable, and also by patient financial constraints. To date, there is 
limited data in regard to screening practices for osteoporosis in people living with 
HIV at other Australian institutions and this study sets a benchmark in order to 
improve.   
 
The prevalence of osteoporosis in those screened was 30% with a 19% rate of fracture 
in the low bone mass group. It is difficult to draw conclusions about the prevalence of 
osteoporosis in the whole cohort because only 93 of those were screened with a 
DEXA scan. The most recent summary statistics from Osteoporosis Australia have 
demonstrated that in Queensland, 14% of people over the age of 50 have osteoporosis, 
and 43% of women and 13% of men over 70 years of age are predicted to have 
osteoporosis.(13) The rates of osteoporosis found in this study are much higher, 
especially in the male population. This highlights the burden of low bone mass in 
people living with HIV, particularly men in this aging cohort and emphasizes the 
importance of screening and treatment. The majority of those diagnosed with 
osteoporosis in this study were on treatment (68% on anti-resorptive therapy and 75% 
vitamin D and calcium supplementation). In regard to anti-resorptive therapy, 
bisphosphonates, specifically alendronate and zoledronic acid, are effective treatment 
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options in HIV patients. Other therapies such as denosumab have not been studied, 
however, it can be assumed they would be effective.(14)  
 
As mentioned above, certain anti-retroviral therapies have been associated with 
reductions in BMD. In this study, a significant number of those with low bone mass 
had a history exposure to both TDF (79%) and protease inhibitors. An association 
between history of TDF exposure and osteoporosis was not found in this cohort 
because the rate of TDF exposure in the whole cohort was substantial (80%). 
Importantly, 45% of those previously on TDF in the low bone mass group had 
transitioned to TAF with only 15 remaining on TDF. A recent switch randomized 
controlled trial of TDF to TAF consisting of 1436 virally suppressed people living 
with HIV demonstrated a mean change in hip BMD of +1.37% in the TAF group and 
-0.26% in the group who remained on TDF. (15) This suggests a benefit from 
switching from TDF. This benefit has also been demonstrated when switching from 
TDF to raltegravir.(16) As mentioned above, however, this may be limited to those 
treated concomitantly with boosted ritonavir or cobicistat and further data is required 
to identify the subset of patients where the benefit is greatest.(8) A randomized trial 
comparing treatment with zoledronic acid (a bisphosphonate) or switching off TDF in 
HIV positive patients with low BMD demonstrated superiority of bisphosphonate 
therapy for both hip and lumbar spine. (17) This highlights that treating osteoporosis 
itself should be the mainstay of management. Equally, in those patients who have low 
BMD but do not meet the criteria for osteoporosis, switching from TDF may reverse 
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the low BMD precluding the need for anti-resorptive therapy as bisphosphonate 
therapy is not risk free. (18) 
 
Various risk factors in addition to antiretroviral therapy have been associated with 
osteoporosis in people living with HIV. These include age, high rates of both smoking 
and alcohol, hepatitis C co-infection and cirrhosis, glucocorticoid use, low BMI and 
HIV infection itself.(4) In our study, the multi-variate logistic regression conducted 
for all patients who had BMD assessed found no association with any of these risk 
factors due largely to the design of the study and small numbers. The prevalence of 
hypogonadism in the low bone mass group was nearly twice as high as in the overall 
cohort. This an interesting finding and will be considered in the future for our 
population.   
 
The limitations of this study include the retrospective nature of the study predisposing 
to recall bias. Associations between various risk factors for osteoporosis in this cohort 
were not established in the logistic regression model due to the methodology of the 
study. This was a secondary aim however, and risk factors have been previously 
described in other studies.  
 
This study provides a foundation for further research at this institution. It also 
highlights that improvement in screening is required and availability of DEXA scan 
should be sought at institutions treating people living with HIV.  
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Conclusions: 
In this HIV cohort, we found a high prevalence of osteoporosis and osteopenia. Only 
60% of those requiring screening underwent BMD assessment indicating that 
improvement in screening practices is required and access to DEXA scans needs to be 
addressed.  
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Table I: Descriptive characteristics for HIV cohort screened with DEXA scan 
Characteristic Total screened 
n=93 
No Low Bone 
Mass * n=23 
Low Bone 
Mass n=70 
P-value 
Age (years)** 63 (62-65) 65 (61-68) 63 (61-65) 0.43 
Gender (male) 83 (89%) 22(96%) 61 (87%) 0.23 
History of 
smoking 
66 (71%) 16 (70%) 50 (71%) 0.86 
Hepatitis C 
coinfection 
6 (7%) 1 (4%) 5 (7%) 0.53 
Duration of HIV 
(years)** 
19 (17-21) 19 (14-23) 18 (16-21) 0.91 
Current TDF 
exposure † 30 (32%) 15 (66%) 15 (21%) 0.01 
Any history of 
TDF exposure 
74 (80%) 19 (83%) 55 (79%) 0.46 
PI exposure 42 (45%) 12 (52%) 30 (43%) 0.44 
BMI (kg/m2)** 25.2 (24.3-
26.2) 
27.4 (24.5-30.3) 24.5 (23.7-
25.4) 
0.01 
Detectable Viral 
load 
5 (5%) 1 (4%) 4 (6%) 0.63 
Hypogonadism 16 (17%) 4 (17%) 12 (17%) 0.61 
Vitamin D 
deficiency 
3 (3% 0 (0%) 3 (6%) 0.68 
History of fracture 13 (14%) 0 (0%) 13 (19%) 0.03 
Fragility fractures 8 (9%) 0 (0%) 8 (12%) 0.19 
* Low Bone Mass = Osteopenia or osteoporosis 
** Mean and 95% CI 
† Current at time of data collection following diagnosis of low bone mass 
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Abstract: 
Background: Adults with human immunodeficiency (HIV) infection commonly experience 
fractures and have a high prevalence of osteoporosis. The reasons for low bone mineral 
density (BMD) in HIV patients are multifactorial and there are now guidelines for screening. 
The aims of this study were to determine the screening practices for osteoporosis at this 
sexual health clinic, the prevalence of osteoporosis and to examine the risk factors for bone 
disease. 
Methods: We performed a retrospective cohort study of all HIV patients attending the 
Sunshine Coast Health Service District Sexual Health Clinic. Via chart review we collected 
the following details: patient demographics, co-morbid conditions, HIV status and anti-
retroviral therapy, BMD screening, fractures, screening for secondary causes of bone disease, 
and treatment interventions for osteoporosis. 
Results: 243 patients with HIV attended the sexual health clinic.  Of these, 149 met screening 
criteria for BMD assessment and 93 (61%) of those eligible underwent BMD examination. In 
those who had a BMD performed, 13 (19%) had sustained a previous fracture, 28 (30%) had 
osteoporosis, 42 (45%) had osteopenia. In the osteoporosis group, 21 (78%) were treated with 
vitamin D and calcium, 7 (26%) had a change in ART, 19 (68%) were treated with anti-
resorptive therapy and 9 received testosterone replacement.  
Conclusions: 
In this cohort, there was a high prevalence of low bone mass and BMD screening rates of 
60%. Our results highlight the importance of this condition and the need to improve 
screening and availability of BMD assessment. 
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Figure 1 Patient Recruitment and BMD screening with DEXA scan.png
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Evaluation of screening practices for low bone mass and prevalence of osteoporosis and 
fractures in people living with HIV attending a sexual health clinic. 
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